# Pipeline Activity Log

> **Review:** Cotrimoxazole prophylaxis for opportunistic infections in children with HIV infection  
> **Date:** 2026-03-26 00:16  
> **Duration:** 17m 13s  
> **Total tokens:** 454,165 (input: 431,303 / output: 22,862)

> **Review URL:** https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003508.pub2/full  
> **Dataset split:** HIV_test  
> **Studies:** 10  

## Resource Usage by Agent

| Agent | Steps | Time | Tokens (in / out) |
|-------|-------|------|-------------------|
| Orchestrator | 16 | 17m 13s | 234,349 / 5,835 |
| Librarian | 3 | 58s | 10,384 / 1,743 |
| Gatekeeper | 8 | 7m 58s | 162,168 / 13,008 |
| Miner | 2 | 38s | 8,526 / 1,028 |
| Critic | 3 | 47s | 15,876 / 1,248 |
| **Total** | **32** | **17m 13s** | **431,303 / 22,862** |

---

## Activity Timeline

### 1. Planning (Orchestrator)

*00:17:17 — 41s — 2,739 tokens*

The orchestrator agent reviewed the review protocol and confirmed that all necessary background information, objectives, and eligibility criteria were already provided, so no external fact-checking was needed upfront. It then planned and initiated the next pipeline steps: first, retrieving all relevant studies by sending the protocol to the librarian agent; next, converting the candidate list into a structured format; and then passing those candidates to the gatekeeper agent to screen them against the review’s selection criteria (e.g., including only randomized trials in children with HIV or infants of HIV-positive mothers). The outcome is a pre-screened list of candidate studies ready for detailed evaluation by downstream agents.

---

### 2. Orchestrator → Librarian

*00:18:31 — 1m 13s — 17,905 tokens*

The orchestrator instructed the librarian agent to search for studies matching the review protocol on cotrimoxazole prophylaxis for children with HIV infection, providing full details on the study question, population, and eligibility criteria. The librarian agent searched for and retrieved a set of potentially relevant studies. The orchestrator confirmed that the librarian completed its task, though the specific number or identity of retrieved studies was not included in this output.

> **Librarian — Step 1:** The librarian agent reviewed the systematic review protocol to confirm the exact scope—specifically, that the review focuses on cotrimoxazole prophylaxis for preventing illness and death in HIV-infected children under 15 and infants under 18 months of HIV-positive mothers. Based on this protocol, the agent then initiated a literature search to identify all relevant studies meeting these inclusion criteria. The outcome was a preliminary set of candidate studies retrieved from the database, ready for the next stage of screening and evaluation.
> **Librarian — Step 2:** The librarian agent searched a literature database for studies that match the review’s specific criteria: cotrimoxazole prophylaxis, HIV infection in children (≤15 years) or infants (<18 months) born to HIV-positive mothers, with comparisons to placebo or no treatment in randomized or quasi-randomized trials. The search returned 10 candidate studies, including key trials such as the CHAP study in Zambia and others focused on pneumocystis pneumonia and other opportunistic infections. All identified studies aligned with the review’s focus on assessing cotrimoxazole’s impact on mortality and illness in this population.
> **Librarian — Step 3 (result):** The librarian agent searched literature databases using a targeted strategy focused on cotrimoxazole prophylaxis, HIV infection, children, and prevention of opportunistic infections. It successfully identified and retrieved 10 candidate studies relevant to the systematic review, including landmark trials like the CHAP study and others examining cotrimoxazole’s use in diverse settings such as sub-Saharan Africa, AIDS-related pneumonia prevention, and HIV disease progression. The final output documents these 10 studies with their titles and abstracts, ready for the next stage of review screening and selection.

---

### 3. Orchestrator (python_interpreter)

*00:18:39 — 9s — 6,160 tokens*

The orchestrator coordinated the pipeline by requesting the list of candidate studies identified by the librarian. It successfully retrieved the studies in a structured, ready-to-use format without any errors or missing data. This step finalized the pool of studies to be evaluated in the next phase of the review process.

---

### 4. Orchestrator → Gatekeeper

*00:22:56 — 4m 16s — 143,913 tokens*

The orchestrator instructed the gatekeeper agent to screen a set of candidate studies for inclusion in the systematic review on cotrimoxazole prophylaxis for HIV-exposed and HIV-infected children. The gatekeeper reviewed each study against predefined eligibility criteria—specifically, randomized or quasi-randomized trials comparing cotrimoxazole to placebo or no treatment in children under 15 with HIV or infants under 18 months with HIV-infected mothers—and classified each as INCLUDE or EXCLUDE with a rationale. The agent successfully completed the screening task, producing initial inclusion/exclusion decisions for all candidate studies.

> **Gatekeeper — Step 1:** The gatekeeper agent prepared 10 candidate studies for screening against the review criteria, which require randomized or quasi-randomized trials of cotrimoxazole prophylaxis versus placebo/no treatment in children under 15 with HIV—or under 18 months with HIV-infected mothers. For Study 1, it assessed that the trial was a double-blind, randomized placebo-controlled study involving HIV-infected Zambian children aged 1–14 years, meeting all key criteria. As a result, the agent decided to INCLUDE this study, with the rationale that it directly evaluated cotrimoxazole prophylaxis in the target population using an appropriate trial design.
> **Gatekeeper — Step 2:** The gatekeeper agent reviewed ten candidate studies to determine if they met the review’s criteria: randomized or quasi-randomized trials comparing cotrimoxazole to placebo/no treatment in children under 15 with HIV infection—or infants under 18 months with HIV-infected mothers. After careful assessment, it included only one study (the CHAP trial), which was a valid randomized trial in HIV-positive children aged 1–14 years; the remaining nine were excluded for failing to meet one or more criteria—most commonly: studying adults instead of children, lacking randomization, or not comparing cotrimoxazole to control. The agent provided clear, criteria-based rationales for each decision.
> **Gatekeeper — Step 3:** The gatekeeper agent reviewed 10 studies to determine which ones met the review’s criteria for inclusion—specifically, randomized trials of cotrimoxazole prophylaxis versus placebo in children under 15 years with HIV infection. It correctly identified only one study (the CHAP trial) as including, due to its randomized design, appropriate population, and intervention aligning with the review’s objectives. The remaining nine studies were excluded, primarily because they focused on adults, lacked randomization or the cotrimoxazole intervention, or were observational or review articles rather than intervention trials.
> **Gatekeeper — Step 4:** The gatekeeper agent reviewed all 10 candidate studies to determine which met the review’s inclusion criteria: randomized trials of cotrimoxazole prophylaxis versus placebo or no treatment in children under 15 with HIV. It included only one study—the CHAP trial in Zambian children—and excluded the other nine because they involved adults, were observational or non-randomized, lacked the required comparison, or did not focus on children. The final decision was highly confident for most exclusions, with one exclusion assessed as medium confidence due to limited age information.
> **Gatekeeper — Step 5:** The gatekeeper agent reviewed 10 candidate studies against the review’s inclusion criteria, which required randomized controlled trials of cotrimoxazole prophylaxis versus placebo in children under 15 years with HIV infection. It included one study (the CHAP trial) that met all criteria and excluded nine others for reasons such as non-randomized design, adult-only participants, use of different interventions, or lack of a comparison group. The final decision list was generated with clear rationales and confidence assessments for each study.
> **Gatekeeper — Step 6 (result):** The gatekeeper agent reviewed 10 candidate studies to determine which met the eligibility criteria for the systematic review on cotrimoxazole prophylaxis in children with HIV. After applying the criteria—specifically requiring a randomized or quasi-randomized trial in children under 15 years comparing cotrimoxazole to placebo or no treatment—only the 2006 CHAP trial qualified for inclusion. The remaining nine studies were excluded for reasons such as including only adults, lacking the intervention or comparison, or being non-experimental designs. This final screening produced a shortlist of one high-quality trial to inform the review’s analysis of cotrimoxazole’s impact on mortality and illness in this population.

---

### 5. Planning (Orchestrator)

*00:23:23 — 28s — 3,790 tokens*

The orchestrator reviewed the review protocol and confirmed the full pipeline steps required to complete the systematic review on cotrimoxazole prophylaxis for HIV-exposed and HIV-infected children. It then prepared a clear, step-by-step plan to delegate each phase—study retrieval, screening, evidence extraction, synthesis, and report formatting—to the appropriate specialized agents. The outcome was a well-structured, executable action plan ready to initiate the pipeline, ensuring alignment with the research question and protocol specifications.

---

### 6. Orchestrator (python_interpreter)

*00:23:36 — 13s — 8,171 tokens*

The orchestrator attempted to verify how many candidate studies were available for review by requesting a summary of the retrieved studies. However, the system encountered an error when trying to process the response—likely because the returned data format didn’t match expectations—causing the check to fail before the count could be confirmed. As a result, the pipeline could not proceed confidently to the next step until the issue was resolved.

> ⚠️ **Error:** Code execution failed at line 'print("Number of candidate studies:", len(candidates_json.get("studies", [])))' due to: InterpreterError: Object {"title": "Cotrimoxazole prophylaxis for opportunistic infections in children with HIV infection", "objective": "To assess the effects of routinely administ

---

### 7. Orchestrator (python_interpreter)

*00:23:48 — 12s — 13,366 tokens*

The orchestrator agent attempted to retrieve and inspect the list of candidate studies for the systematic review, but encountered an error because the expected data structure was not as anticipated—it could not directly access the “studies” key from the returned information. Instead of failing, the agent flagged the issue to allow for a more robust data-handling approach in subsequent steps. The outcome was a clearer understanding of the data format discrepancy, prompting the pipeline to adapt its strategy for sourcing and validating study metadata.

> ⚠️ **Error:** Code execution failed at line 'candidates_list = candidates_dict["studies"]' due to: InterpreterError: Could not index {"title": "Cotrimoxazole prophylaxis for opportunistic infections in children with HIV infection", "objective": "To assess the effects of routinely administered cotrimoxazole on dea

---

### 8. Orchestrator (python_interpreter)

*00:24:01 — 13s — 18,636 tokens*

The orchestrator agent identified that candidate study data was being delivered as a text string instead of a structured format, so it manually converted the string into a usable list of studies. After parsing, it confirmed there were 10 relevant studies, each with titles and key details like objective and background, ready for the next steps in the review process.

---

### 9. Planning (Orchestrator)

*00:24:43 — 42s — 14,493 tokens*

The orchestrator reviewed the systematic review plan and confirmed the next priority: to coordinate the full evidence synthesis pipeline. It instructed the librarian to search for relevant studies, then processed the returned candidates through study selection (gatekeeper), data extraction (miner), evidence synthesis (critic), and reporting (formatter), finally saving the structured results. The pipeline successfully generated a final, formatted Markdown report summarizing the evidence on cotrimoxazole prophylaxis for children with HIV, as requested.

---

### 10. Orchestrator → Gatekeeper

*00:29:13 — 4m 29s — 58,503 tokens*

The orchestrator instructed the gatekeeper agent to screen a list of candidate studies for inclusion in a systematic review on cotrimoxazole prophylaxis for children with HIV. The gatekeeper applied strict criteria—requiring randomized or quasi-randomized trials of cotrimoxazole versus placebo/no treatment in children under 15 with HIV or infants under 18 months with HIV-positive mothers—and generated_INCLUDE or EXCLUDE_ decisions for each study, along with clear justifications. The screening process completed successfully, resulting in a final set of studies selected for full-text review.

> **Gatekeeper — Step 1:** The gatekeeper agent reviewed 10 candidate studies against the review criteria: randomized or quasi-randomized trials comparing cotrimoxazole to placebo or no treatment in children under 15 with HIV infection or infants under 18 months with HIV-infected mothers. It assessed each study’s title and abstract to determine inclusion, and the first study met all criteria—being a double-blind randomized placebo-controlled trial in children aged 1–14 with HIV infection—so it was selected for inclusion. The agent returned its decisions and supporting rationale for all 10 studies, with six included and four excluded based on factors such as non-randomized design, inclusion of adults only, or participants outside the specified age or HIV-status criteria.
> **Gatekeeper — Step 2 (result):** The gatekeeper agent reviewed 10 candidate studies to determine which met the review criteria: a randomised or quasi-randomised trial comparing cotrimoxazole to placebo or no treatment in children under 15 with HIV infection, or children under 18 months with HIV-infected mothers. After careful assessment, only one study—the CHAP trial—fully satisfied all criteria, as it was a double-blind randomised placebo-controlled trial in children aged 1–14 with HIV infection; the remaining nine were excluded for reasons such as enrolling adults only, lacking randomisation, not testing cotrimoxazole, or not focusing on HIV-positive children. The final output lists a single included study and nine exclusions, all with high confidence.

---

### 11. Orchestrator (python_interpreter)

*00:29:45 — 32s — 21,189 tokens*

The orchestrator agent process identified a single study meeting the inclusion criteria from the pool of candidate records. It used the gatekeeper’s screening decision—along with the list of candidate studies—to extract and format the relevant study information, resulting in one high-priority trial being selected for further processing. The selected study is the 2004 CHAP trial, which evaluated cotrimoxazole prophylaxis in HIV-infected Zambian children and demonstrated a significant reduction in mortality. This study is now ready to be passed to the next stage of the review pipeline for detailed analysis.

---

### 12. Orchestrator → Miner

*00:30:34 — 49s — 31,748 tokens*

The orchestrator directed the miner agent to extract key evidence from the CHAP trial, a study included in the review on cotrimoxazole prophylaxis for HIV-infected children in Zambia. The miner successfully compiled structured data on the study’s population (534 HIV-infected children aged 1–14), intervention (daily cotrimoxazole), comparator (placebo), and outcomes—including a 43% reduction in mortality (hazard ratio 0.57, *p*=0.0002) and similar rates of severe adverse events between groups. This structured evidence is now ready for integration into the review’s analysis.

> **Miner — Step 1:** The agent extracted structured evidence from one included study, identifying key elements of the research design (population, intervention, comparison, outcomes) and quantifying the main findings. Specifically, it determined that cotrimoxazole prophylaxis significantly reduced mortality in HIV-infected Zambian children (hazard ratio 0.57, 95% CI 0.43–0.77), with a low rate of serious adverse events in both groups. This evidence supports the conclusion that routine cotrimoxazole use improves survival in this population.
> **Miner — Step 2 (result):** The miner agent extracted detailed evidence from the CHAP trial, capturing key study details (participants, design, setting), the intervention (daily co-trimoxazole prophylaxis) and comparator (placebo), and quantified outcomes including mortality (hazard ratio 0.57), adverse events, and neutropenia. It synthesized the trial’s main findings—such as a 28% vs. 42% mortality rate favoring co-trimoxazole and no meaningful increase in serious side effects—along with contextual notes about the early trial stoppage and study quality. The final structured output provides a comprehensive,-ready-for-analysis summary of the study’s methodology and results.

---

### 13. Planning (Orchestrator)

*00:31:23 — 49s — 16,844 tokens*

The orchestrator reviewed the systematic review task—focused on cotrimoxazole’s effects for preventing opportunistic infections in HIV-affected children—and confirmed it needed to coordinate a full evidence synthesis pipeline. It then designed and set up the sequence of specialized agent tasks: retrieving relevant studies, screening them for inclusion, extracting key data, critically appraising the evidence, and generating a final report. With the plan now clear and ready for execution, the orchestrator prepared to activate the pipeline to produce a structured, reproducible review outcome.

---

### 14. Orchestrator → Critic

*00:33:00 — 1m 36s — 42,391 tokens*

The orchestrator tasked the critic agent with evaluating the quality of evidence from the CHAP trial and synthesizing the findings for the systematic review. The critic assessed the trial as high-quality overall, highlighting strengths like randomization, blinding, and clear mortality benefit, while noting limitations such as single-center setting and incomplete HIV confirmation. The outcome was a structured assessment showing low risk of bias in most areas, high confidence in the mortality reduction, and a supportive narrative synthesis for cotrimoxazole prophylaxis in HIV+ children.

> **Critic — Step 1:** The critic agent attempted to evaluate the quality and synthesize the evidence extracted from the literature, but encountered an error during the quality assessment step. The error occurred because the function expected a different set of input parameters than those provided—specifically, it did not accept the review objective as input. As a result, the agent was unable to complete the quality assessment, though the synthesis step (which followed in the code) was not reached.
> **Critic — Step 2:** The critic evaluated the quality of the extracted evidence, confirming that the main study was a well-conducted randomized trial. It then synthesized the key findings, highlighting a significant reduction in mortality (hazard ratio 0.57) with co-trimoxazole prophylaxis in HIV-infected children, along with a possible increase in neutropenia (though not statistically significant). The overall assessment supported the reliability of the mortality result despite minor limitations, such as the use of clinical rather than lab-confirmed HIV status in the original abstract.
> **Critic — Step 3 (result):** The critic agent evaluated the quality of the CHAP trial, concluding it is high-quality due to its rigorous design, robust statistical findings, and consistent benefits across subgroups, while acknowledging limitations such as the single-center setting and partial reliance on clinical (not lab-confirmed) HIV diagnosis. It then synthesized the evidence into a clear narrative, emphasizing the trial’s strong support for cotrimoxazole prophylaxis reducing mortality in HIV-infected children in resource-limited settings, though noting uncertainty around prevention of specific infections like PCP due to limited data.

---

### 15. Orchestrator (python_interpreter)

*00:33:46 — 47s — 26,952 tokens*

The orchestrator agent compiled the final systematic review report by gathering inputs from all specialized agents (screening, evidence extraction, and synthesis) and formatting them into a clear Markdown document. It then securely stored this report, along with structured evidence data (including screening decisions, extracted findings, and synthesis insights), into a dedicated output folder for reproducibility and future access. The process completed successfully, yielding a ready-to-use report and a comprehensive, organized dataset of the review’s evidence.

---

### 16. Final Output (Orchestrator)

*00:33:50 — 3s — 27,365 tokens*

The orchestrator agent performed a final review of the systematic search and screening process for studies on cotrimoxazole prophylaxis in children with HIV. It confirmed that only one study met all eligibility criteria (a randomised controlled trial in children aged 1–14), while the other nine were excluded—primarily because they involved adults, lacked randomisation, or did not test cotrimoxazole in comparison to a control group. The agent then compiled and returned the complete, verified report as the final output, documenting both the included and excluded studies with clear reasons for each decision.

---
